emerg
infecti
diseas
pose
constant
threat
global
health
global
economi
vast
major
diseas
zoonos
occur
human
environment
factor
forc
unintend
overlap
previous
distinct
ecolog
nich
overlap
increas
chanc
virus
jump
host
speci
andor
gener
new
crossov
speci
case
zoonot
virus
ill
adapt
new
human
host
highli
pathogen
infect
virus
lead
rapidli
progress
sever
diseas
high
fatal
filovirus
ebola
viru
ebov
marburg
viru
henipavirus
hendra
viru
nipah
viru
niv
coronavirus
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
lethal
exampl
recent
addit
virus
famili
arenavirida
junin
viru
lassa
viru
bunyavirida
includ
divers
hantavirus
rift
valley
fever
viru
rvfv
flavivirida
dengu
viru
denv
west
nile
viru
wnv
may
repres
even
greater
threat
futur
global
climat
chang
increas
geograph
rang
anim
arthropod
hiv
arguabl
obviou
exampl
zoonosi
disrupt
global
health
economi
public
health
intervent
combin
concert
effort
develop
specif
drug
hiv
yield
laudabl
success
develop
specif
drug
target
differ
aspect
hiv
life
cycl
result
potent
antiretrovir
combin
drug
therapi
save
innumer
live
success
antiretrovir
drug
develop
recapitul
latest
gener
potent
diseaseerad
antihepat
c
viru
hcv
drug
target
specif
hcv
protein
success
showcas
power
tradit
pathogenspecif
drug
develop
paradigm
well
practis
pharmaceut
industri
despit
mani
success
one
drug
approach
antivir
drug
develop
strategi
may
inadequ
respond
increas
divers
virus
caus
signific
diseas
human
exampl
industri
antivir
drug
develop
understand
driven
econom
incent
mean
list
clinic
activ
antivir
approv
us
fda
european
medicin
agenc
ema
domin
antihiv
antihcv
antiherpesviru
antiinfluenza
viru
drug
given
increas
number
emerg
reemerg
viral
zoonos
close
half
million
unknown
mammalian
virus
predict
present
wildlif
reservoir
remain
tradit
virusspecif
paradigm
antivir
drug
develop
unlik
result
time
effect
therapi
numer
pathogen
caus
rare
lethal
infect
observ
underscor
need
broadspectrum
antivir
act
multipl
virus
target
common
life
cycl
rather
specif
viral
protein
importantli
ribavirin
current
broadspectrum
antivir
purportedli
effect
variou
rna
virus
consensu
mechan
action
moa
perhap
ribavirin
multipl
mode
action
work
differ
way
differ
virus
ideal
broadspectrum
antivir
one
target
common
essenti
viral
function
properti
notabl
vast
major
viral
pathogen
present
emerg
infecti
diseasespathogen
list
us
nation
institut
allergi
infecti
diseas
niaid
smallpox
viru
viral
haemorrhag
fever
virus
arenavirus
bunyavirus
flavivirus
filovirus
henipavirus
coronavirus
arbovirus
caus
encephalitid
wnv
cite
membraneenvelop
virus
order
virus
replic
need
gain
access
metabol
resourc
within
host
cell
occur
process
involv
viru
host
cell
membran
fusion
requir
viral
fusion
protein
take
place
either
directli
cell
surfac
later
endocyt
compart
despit
divers
array
viral
fusion
protein
vari
moa
underli
biophys
biochem
featur
membran
fusion
process
common
among
envelop
virus
target
conserv
featur
biophys
properti
viral
lipid
membran
host
factor
requir
effici
membran
fusion
emerg
new
paradigm
develop
broadspectrum
antivir
furthermor
featur
encod
viral
genom
suggest
antivir
strategi
also
probabl
increas
barrier
resist
review
discuss
common
featur
underli
fusion
viru
cell
membran
present
compound
owe
abil
target
differ
step
process
potenti
broadspectrum
antivir
also
highlight
emerg
antivir
wellestablish
moa
potenti
clinic
develop
one
strategi
design
broadspectrum
antivir
target
protein
involv
viral
fusion
process
includ
viral
fusion
protein
fusion
inhibitor
greater
understand
differ
step
involv
cascad
conform
chang
result
membran
fusion
biochem
character
domain
expos
phi
variou
fusion
protein
led
ration
design
peptid
inhibitor
antagon
transit
fold
extend
phi
highli
stabl
postfus
conform
fig
first
proof
concept
came
studi
peptid
amino
acid
deriv
carboxytermin
heptad
repeat
domain
class
fusion
protein
peptid
call
also
known
enfuvirtid
fuzeon
roch
clinic
use
salvag
therapi
patient
infect
multidrugresist
hiv
design
target
complementari
domain
tran
fit
interstic
trimer
core
phi
prevent
refold
cognat
domain
ci
thu
antagon
transit
phi
stabl
trimerofhairpin
structur
propos
act
dominantneg
inhibitor
inhibit
entri
much
greater
potenc
lower
halfmaxim
inhibitori
concentr
would
expect
affin
trimer
core
howev
resist
mutat
often
occur
outsid
complementari
region
viral
isol
treat
patient
even
report
becom
depend
entri
indic
still
fulli
understand
nevertheless
paradigm
establish
encourag
develop
analog
fusion
inhibitor
class
viral
fusion
also
led
investig
diiideriv
peptid
inhibitor
class
ii
fusion
protein
basi
function
homolog
domain
class
fusion
protein
diii
domain
class
ii
fusion
although
peptidebas
approach
may
broadli
applic
across
class
viral
fusion
protein
gener
actual
peptid
therapeut
like
specif
viru
close
relat
variant
develop
howev
peptid
deriv
domain
fusion
protein
unexpectedli
display
activ
unrel
virus
exampl
recent
describ
peptid
deriv
membraneproxim
stem
region
rvfv
gc
class
ii
fusion
protein
inhibit
entri
rvfv
also
ebov
vsv
encod
class
class
iii
fusion
protein
structur
model
indic
peptid
compat
expos
complementari
hydrophob
domain
class
fusion
protein
propos
moa
remain
rigor
test
conformationalchang
inhibitor
alloster
control
protein
function
exchang
emerg
theme
broad
scientif
interest
especi
metast
protein
involv
cell
exampl
thiol
isomeras
prototyp
cell
surfac
protein
disulfid
isomeras
encod
implic
rearrang
intramolecular
disulfid
bond
occur
viral
envelop
protein
fusion
review
ref
fig
larg
famili
pdi
protein
usual
resid
endoplasm
reticulum
er
studi
cell
surfac
pdi
regard
viral
entri
unless
otherwis
specifi
typic
refer
howev
lack
specif
inhibitor
pdi
famili
member
except
monoclon
coupl
lack
mechan
account
cell
surfac
retent
pdi
stymi
investig
pdi
potenti
therapeut
target
furthermor
assumpt
pdi
druggabl
target
owe
ubiquit
function
er
chaperon
inhibit
would
lead
unaccept
toxic
also
hamper
search
specif
pdi
inhibitor
discoveri
recent
year
may
offer
new
opportun
investig
pdi
druggabl
target
potenti
broadspectrum
antivir
exampl
discoveri
galectin
bind
retain
increas
activ
perhap
also
known
also
known
surfac
provid
mechanist
basi
longstand
observ
pdi
activ
surfac
lymphocyt
galectin
effect
function
oligom
form
glycoprotein
lattic
cell
surfac
cluster
cognat
furthermor
galectin
enhanc
hiv
entri
host
cell
inhibit
monoclon
suggest
cell
surfac
inde
modul
viru
entri
sever
studi
identifi
compound
form
specif
thiol
coval
adduct
cystein
residu
activ
site
therefor
serv
specif
propyno
acid
carbamoyl
methylamid
identifi
screen
novel
antitumour
wherea
activ
identifi
screen
cytoprotect
compound
cellular
model
huntington
pdi
secret
platelet
endotheli
cell
thrombogen
addit
screen
analys
potent
inhibitor
extracellular
pdi
candid
antithrombot
therapi
identifi
also
known
rutin
highli
specif
select
inhibit
relat
pdi
famili
member
also
known
thioredoxin
effect
relev
anim
model
untoward
toxic
concentr
use
thu
pdi
inhibitor
success
develop
treat
could
leverag
potenti
broadspectrum
fig
revers
tradit
paradigm
reli
test
activ
differ
compound
specif
viru
highli
specif
pdi
inhibitor
could
use
screen
set
suscept
viral
pathogen
pharmacokinet
safeti
toxic
data
alreadi
obtain
lead
compound
could
appli
relev
anim
model
infect
clearli
side
effect
drug
balanc
potenti
efficaci
antivir
nevertheless
repurpos
fdaapprov
drug
treat
rare
lethal
emerg
infecti
diseas
strategi
endors
fda
medic
countermeasur
initi
mcmi
fdawid
effort
set
facilit
avail
drug
countermeasur
need
control
emerg
infecti
diseas
specul
nitazoxanid
ntz
thiazolid
antiparasit
agent
recent
propos
potenti
pdi
demonstr
broad
antivir
activ
vitro
singl
drug
synergi
howev
still
unclear
whether
antivir
activ
ntz
directli
relat
antipdi
activ
arbidol
arb
also
known
umifenovir
wellknown
indol
deriv
broadspectrum
antivir
activ
popular
treatment
respiratori
infect
russia
china
unfortun
report
moa
also
broad
least
case
influenza
viru
viral
resist
arb
map
class
fusion
protein
haemagglutinin
ha
arbresist
ha
variant
mediat
membran
fusion
higher
ph
wildtyp
convers
arbbound
ha
variant
requir
lower
ph
wildtyp
protein
transit
lowph
form
phi
data
indic
arbresist
easili
destabil
suggest
arb
inhibit
influenza
viru
entri
stabil
ha
prefus
conform
fig
whether
arb
similar
moa
phdepend
virus
remain
seen
ntz
arb
exemplifi
promis
broadspectrum
antivir
candid
immedi
use
patient
combin
good
bioavail
safe
record
use
patient
oral
formul
avail
arb
broadli
distribut
russia
yet
approv
fda
ema
use
western
countri
ntz
approv
fda
treatment
infect
giardia
lamblia
alinia
romark
laboratori
lc
current
global
phase
iii
clinic
trial
influenza
ntz
arb
appear
safe
clinic
profil
offlabel
use
treatment
suscept
viral
pathogen
may
thu
warrant
guid
proper
surrog
anim
efficaci
studi
option
avail
addit
tradit
compound
target
protein
mediat
viral
fusion
emerg
paradigm
broadspectrum
antivir
point
lipid
viru
host
cell
membran
potenti
target
block
viral
fusion
entri
virolyt
antivir
peptid
virolyt
antivir
peptid
avp
reminisc
broadspectrum
pleiotrop
antimicrobi
peptid
amp
part
innat
immun
defenc
mechan
present
kingdom
life
date
bestcharacter
avp
gener
small
kda
cation
amphiphil
peptid
activ
probabl
reli
interfaci
inde
avp
engag
electrostat
andor
hydrophob
interact
hydrophob
surfac
fusion
protein
transient
expos
fusion
process
avp
also
interact
membran
abil
avp
interact
fusion
protein
exemplifi
aforement
fusion
inhibitor
peptid
fig
contrast
abil
avp
interact
membran
lipid
exemplifi
peptid
deriv
nonstructur
protein
hcv
wasp
venom
secretagogu
toxin
mastoparan
deriv
peptid
detergentlik
properti
fig
display
potent
virolyt
activ
variou
envelop
virus
includ
member
flavivirida
paramyxovirida
famili
wnv
denv
hcv
human
respiratori
syncyti
viru
rsv
other
influenza
obviou
differ
could
discern
sensit
resist
virus
puzzl
select
lytic
avp
toward
target
remain
subject
ongo
perhap
case
sever
select
avp
resid
distinct
lipid
composit
viral
target
membran
membran
host
cell
viral
lipidom
profil
help
address
verac
hypothesi
databas
experiment
valid
avp
indic
avp
increasingli
investig
therapeut
util
lack
cohes
moa
like
imped
clinic
applic
near
futur
membran
curvatur
fluiditi
membran
fluiditi
essenti
paramet
govern
energet
membran
curvatur
transit
occur
membran
box
lipid
composit
main
determin
membran
fluiditi
imbal
membran
interfac
posit
neg
affect
progress
fusion
process
inde
positivetoneg
membran
curvatur
transit
occur
fusion
fig
fruit
interrog
variou
lipid
either
support
antagon
geometr
constraint
fusion
process
exampl
coneshap
lipid
cholesterol
oleic
acid
tend
favour
membran
fusion
promot
neg
curvatur
therefor
facilit
hemifus
contrast
invertedconeshap
lipid
also
call
wedgelik
lipid
lysolipid
includ
lysophosphatidylcholin
lpc
inhibit
fusion
increas
posit
curvatur
viral
membran
fig
thu
rais
energi
barrier
must
overcom
product
fusion
mediat
viral
fusion
sterol
lipid
composit
essenti
membran
curvatur
fluiditi
remov
andor
addit
speci
viral
andor
cellular
membran
evalu
antivir
strategi
interest
exampl
come
socal
polyunsatur
ertarget
liposom
perl
origin
develop
deliv
antivir
drug
cargo
serendipit
perl
found
broadspectrum
antivir
activ
hiv
hcv
hepat
b
viru
hbv
even
antivir
drug
cargo
load
mechanist
investig
indic
perl
trigger
reduct
cellular
level
cholesterol
coneshap
lipid
tend
favour
membran
fusion
virus
even
effici
clinic
approv
cholesterollow
drug
lovastatin
mevacor
merck
also
antivir
effect
hcv
tabl
perltrigg
cellular
cholesterol
deplet
result
decreas
entri
suscept
virus
sensit
reduc
level
cholesterol
cell
surfac
addit
virus
produc
perltreat
cell
reduc
infect
owe
lower
cholesterol
content
lipid
envelop
bud
virion
fig
phenotyp
could
rescu
addit
exogen
result
confirm
import
cholesterol
within
cellular
viral
membran
least
three
test
virus
hiv
hcv
hbv
thu
perltrigg
cellular
cholesterol
reduct
seem
impair
one
step
replic
cycl
suscept
virus
although
capabl
attract
exact
mechan
mechan
perl
antivir
activ
suscept
virus
remain
character
offtarget
effect
perlinduc
signal
cascad
await
better
definit
invertedconeshap
compound
invertedconeshap
speci
lysolipid
known
impair
fusion
stabil
viral
lipid
membran
state
posit
membran
curvatur
rais
energet
cost
need
viral
fusion
fig
howev
compound
may
also
act
last
step
membran
fusion
stabil
highli
posit
curv
pore
edg
fig
therebi
prevent
notabl
lysolipid
broadli
antivir
also
cytotox
unstabl
addit
antifusogen
effect
realiz
millimolar
concentr
readili
revers
although
properti
bode
well
use
lysolipid
experiment
tool
hinder
therapeut
potenti
compound
nonetheless
lysolipid
moa
inspir
ration
design
novel
class
broadspectrum
antivir
term
rigid
amphipath
fusion
inhibitor
rafi
rafi
nonlipid
invertedconeshap
molecul
made
conjug
larg
bulki
hydrophil
head
nucleosid
deriv
smaller
rigid
planar
hydrophob
rafi
geometr
reminisc
lysolipid
exhibit
broadspectrum
antivir
activ
sever
envelop
virus
herp
simplex
viru
hsv
influenza
viru
vsv
hcv
nonenvelop
virus
although
relationship
analys
sar
analys
show
consist
propos
moa
involv
geometr
antagon
neg
membran
curvatur
subset
rafi
appear
activ
furthermor
rafi
seem
act
irrevers
tensofnanomolar
rang
collect
observ
inconsist
pure
geometr
moa
suggest
addit
mechan
respons
antivir
effect
mediat
therefor
although
greater
potenc
invertedconeshap
rafi
rel
lysolipid
nanomolar
rang
rafi
versu
millimolar
rang
lysolipid
support
potenti
broadspectrum
antivir
addit
studi
need
clarifi
moa
compound
lipid
oxid
group
amphiphil
thiazolidin
deriv
exemplifi
small
molecul
found
exhibit
broadspectrum
antivir
activ
could
inhibit
virus
differ
famili
envelop
virus
test
includ
variou
virus
filovirida
paramyxovirida
arenavirida
flavivirida
herpesvirida
famili
nonenvelop
compound
lightactiv
membranetarget
singlet
oxygen
gener
also
known
type
ii
photosensit
gener
compound
oxid
cc
doubl
bond
present
unsatur
phospholipid
result
cistotran
isomer
bond
introduc
polar
hydroperoxi
group
highli
hydrophob
acyl
chain
photochem
induc
chang
alter
critic
biophys
properti
membran
although
exact
chang
occur
follow
lipid
oxid
unknown
first
project
plasma
membran
surfac
area
occupi
oxid
phospholipid
predict
increas
owe
migrat
hydroperoxi
group
polar
plane
surfac
second
oxid
phospholipid
predict
cluster
microdomain
order
reduc
hydrophob
repuls
forc
newli
incorpor
polar
fig
inde
featur
physic
observ
nanoscop
scale
use
atom
forc
microscopi
enabl
quantit
assess
decreas
membran
thick
expans
area
per
unsatur
altogeth
rearrang
membran
nanoarchitectur
result
increas
posit
curvatur
reduc
fluiditi
togeth
increas
energet
requir
membran
fusion
box
use
panopli
assay
involv
model
membran
live
virus
treat
deriv
lipid
oxid
viral
membran
shown
correl
increas
lipid
pack
reduc
membran
fluiditi
also
link
impair
viral
furthermor
observ
extend
group
thiazolidin
deriv
followup
class
novel
deriv
exampl
also
chemic
unrel
rafi
inde
close
examin
activ
rafi
reveal
consist
presenc
hydrophob
polycycl
perylen
group
reminisc
wellknown
photosensit
exampl
hypocrellin
hypericin
suggest
rafi
act
photosensit
followup
studi
confirm
antivir
activ
exemplar
rafi
abolish
absenc
light
thu
strictli
depend
light
exposur
furthermor
antivir
activ
could
revers
scaveng
character
type
ii
membranetarget
photosensit
regard
antivir
converg
moa
chemic
distinct
class
broadspectrum
antivir
target
lipid
compon
membran
fusion
underscor
generaliz
propos
moa
despit
encourag
vivo
activ
ref
clinic
potenti
membranetarget
photosensit
broadspectrum
antivir
vivo
seem
current
limit
photophys
hurdl
includ
depth
tissu
penetr
visibl
light
nonetheless
advanc
photochemistri
nanotechnolog
may
help
overcom
hurdl
exampl
recent
develop
includ
upconvert
fluoresc
nanoparticl
abl
convert
tissuepenetr
long
wavelength
rel
shorter
within
absorpt
studi
establish
novel
paradigm
broadspectrum
antivir
identifi
moa
membraneintercal
photosensit
involv
photooxid
unsatur
phospholipid
lead
biophys
chang
neg
affect
abil
viral
membran
undergo
fusion
also
compound
effect
antivir
concentr
induc
notic
biophys
chang
metabol
activ
cell
membran
also
contain
unsatur
phospholipid
target
ref
due
fact
biogen
cellular
membran
benefit
cellular
repar
capac
static
viral
membran
lack
futur
class
broadspectrum
antivir
may
exploit
gener
principl
phospholipidspecif
antibodi
final
bavituximab
peregrin
pharmaceut
repres
one
clinic
promis
broadspectrum
antivir
paradigm
bavituximab
immunoglobulin
monoclon
antibodi
direct
anion
phospholipid
phosphatidylserin
phosphatidylserin
normal
restrict
inner
leaflet
cellular
plasma
membran
flip
expos
cell
surfac
apoptot
viral
replic
often
trigger
cellular
apoptot
state
neovirion
bud
produc
cell
piec
membran
contain
phosphatidylserin
outer
leaflet
phosphatidylserin
inde
detect
variou
viral
envelop
target
uniqu
featur
select
exposur
phosphatidylserin
viral
envelop
membran
healthi
cell
bavituximab
potenti
use
broadspectrum
antivir
fig
inde
bavituximab
prove
efficaci
murin
cytomegaloviru
mcmv
arenaviru
pichind
viru
bavituximab
current
evalu
variou
haemorrhag
fever
virus
hiv
phase
phase
ii
clinic
trial
treatment
chronic
hcv
infect
coinfect
hiv
hcv
potenti
use
bavituximab
viral
diseas
futur
greatli
enhanc
current
evalu
antineoplast
therapeut
howev
exact
rang
virus
display
suffici
amount
phosphatidylserin
outer
leaflet
membran
success
target
bavituximab
remain
determin
despit
divers
array
viral
fusion
mechan
even
wider
rang
put
broadspectrum
antivir
character
target
cell
membran
fusion
process
antivir
broad
spectrum
sens
target
virus
within
famili
protein
within
viral
fusion
protein
class
wherea
other
broad
spectrum
sens
target
requir
particular
fusion
trigger
furthermor
antivir
truli
broad
spectrum
target
physicochem
basi
underli
membran
fusion
event
exploit
physiolog
differ
static
viral
membran
metabol
activ
cellular
membran
repar
capac
exampl
avp
sterolbind
agent
membraneintercal
photosensit
may
damag
viru
cell
membran
thu
toxic
extent
howev
key
paradigm
recogn
physiolog
differ
inact
viral
activ
cellular
membran
exploit
develop
broadspectrum
antivir
relev
issu
whether
drug
toxic
known
toxic
certain
cellular
process
arbitrari
concentr
whether
drug
toxic
antivir
concentr
treatment
condit
addit
calcul
much
toxic
accept
must
depend
acut
pathogen
viral
infect
avail
lack
thereof
effect
therapeut
option
exampl
chronic
infect
hiv
hcv
drug
need
taken
daili
prolong
period
therapeut
select
longterm
safeti
issu
paramount
case
abund
highli
effect
therapi
alreadi
exist
barrier
use
broadspectrum
antivir
high
convers
current
ebola
epidem
west
africa
shortterm
toxic
potenti
antivir
would
weigh
lack
effect
option
valid
reason
support
efficaci
potenti
drug
rapid
expans
broadspectrum
antivir
approach
directli
indirectli
target
lipid
involv
viral
membran
underscor
need
comprehens
character
viral
lipidom
lipidom
studi
alreadi
reveal
cell
activ
lipid
composit
primari
human
cell
type
thu
like
virus
grown
commonli
use
laboratori
cell
line
accur
reflect
viral
phenotyp
caus
transmiss
infecti
diseas
affect
efficaci
antivir
call
standard
protocol
cell
type
use
antivir
evalu
standard
acceler
translat
develop
novel
broadspectrum
antivir
exampl
use
relev
vitro
surrog
system
use
human
pluripot
stem
cellderiv
primari
cell
type
determin
antivir
efficaci
therapeut
index
halfmaxim
cytotox
concentr
could
provid
biolog
relev
inform
even
antivir
test
anim
similarli
recent
advanc
threedimension
bioprint
microfluid
organsonchip
allow
gener
relev
tissu
model
drug
discoveri
thu
sar
studi
broadspectrum
antivir
target
viral
fusion
even
hone
relev
tissu
model
eventu
anim
test
altogeth
technolog
facilit
translat
basic
understand
viral
fusion
process
broadspectrum
therapi
target
process
